Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report

• We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification. • The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels. • Pazopanib, a multi-tyrosine kinase inhibitor, was effective aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawayama, Saki, Murakami, Ryusuke, Aki, Megumi, Kawaguchi, Yusuke, Takao, Yumi, Nonogaki, Hirofumi, Goto, Tomoyuki, Yamauchi, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108727/
https://www.ncbi.nlm.nih.gov/pubmed/35586703
http://dx.doi.org/10.1016/j.gore.2022.100993
_version_ 1784708767234916352
author Sawayama, Saki
Murakami, Ryusuke
Aki, Megumi
Kawaguchi, Yusuke
Takao, Yumi
Nonogaki, Hirofumi
Goto, Tomoyuki
Yamauchi, Chikako
author_facet Sawayama, Saki
Murakami, Ryusuke
Aki, Megumi
Kawaguchi, Yusuke
Takao, Yumi
Nonogaki, Hirofumi
Goto, Tomoyuki
Yamauchi, Chikako
author_sort Sawayama, Saki
collection PubMed
description • We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification. • The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels. • Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with FGFR1 amplification. • Pazopanib maintained the patient’s quality of life for a certain period.
format Online
Article
Text
id pubmed-9108727
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91087272022-05-17 Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report Sawayama, Saki Murakami, Ryusuke Aki, Megumi Kawaguchi, Yusuke Takao, Yumi Nonogaki, Hirofumi Goto, Tomoyuki Yamauchi, Chikako Gynecol Oncol Rep Case Report • We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification. • The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels. • Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with FGFR1 amplification. • Pazopanib maintained the patient’s quality of life for a certain period. Elsevier 2022-05-02 /pmc/articles/PMC9108727/ /pubmed/35586703 http://dx.doi.org/10.1016/j.gore.2022.100993 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sawayama, Saki
Murakami, Ryusuke
Aki, Megumi
Kawaguchi, Yusuke
Takao, Yumi
Nonogaki, Hirofumi
Goto, Tomoyuki
Yamauchi, Chikako
Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title_full Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title_fullStr Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title_full_unstemmed Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title_short Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
title_sort efficacy of pazopanib in fgfr1-amplified uterine carcinosarcoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108727/
https://www.ncbi.nlm.nih.gov/pubmed/35586703
http://dx.doi.org/10.1016/j.gore.2022.100993
work_keys_str_mv AT sawayamasaki efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT murakamiryusuke efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT akimegumi efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT kawaguchiyusuke efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT takaoyumi efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT nonogakihirofumi efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT gototomoyuki efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport
AT yamauchichikako efficacyofpazopanibinfgfr1amplifieduterinecarcinosarcomaacasereport

Ejemplares similares